ERBB2 and neoplasm: The increase of the CD16+ cell rate over time after treatment indicated the enrichment of an important fraction of mature NK cells, the only population of these cells expressing KIR receptors and functionally equipped to trigger ADCC in HER2-expressing tumor cells in the presence of trastuzumab.